[go: up one dir, main page]

WO2008140081A1 - リポソームおよびリポソームの製造方法 - Google Patents

リポソームおよびリポソームの製造方法 Download PDF

Info

Publication number
WO2008140081A1
WO2008140081A1 PCT/JP2008/058768 JP2008058768W WO2008140081A1 WO 2008140081 A1 WO2008140081 A1 WO 2008140081A1 JP 2008058768 W JP2008058768 W JP 2008058768W WO 2008140081 A1 WO2008140081 A1 WO 2008140081A1
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
liposome
functional
types
membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/058768
Other languages
English (en)
French (fr)
Inventor
Takeshi Isoda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Konica Minolta Inc
Original Assignee
Konica Minolta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Konica Minolta Inc filed Critical Konica Minolta Inc
Priority to EP08752648.9A priority Critical patent/EP2153820A4/en
Priority to JP2009514167A priority patent/JP5532921B2/ja
Priority to EP19153810.7A priority patent/EP3494964B1/en
Priority to US12/599,159 priority patent/US20100215582A1/en
Publication of WO2008140081A1 publication Critical patent/WO2008140081A1/ja
Anticipated expiration legal-status Critical
Priority to US14/598,603 priority patent/US9980908B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A61K8/416—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

　本発明は、リポソームであって、１種または２種以上の機能性脂質（たとえば、荷電脂質、分極性脂質、脂溶性脂質、水溶性脂質など他の化合物と化学的に相互作用するもの）を含む脂質で構成されている内膜と、１種または２種以上の機能性脂質を含むまたは含まない脂質で構成されている外膜とからなる脂質二分子膜層を有し、少なくとも、当該内膜に含まれるいずれか１つの種類の機能性脂質については、その内膜における量が、その外膜における量を上回るとの条件を満たすことを特徴とし、造影剤（水酸基を有する中性物質）や抗癌活性を有するsiRNA（アニオン性物質）などを内包させるリポソームとして好適であり、薬剤類の内包率や分散安定性、コントロールリリースなどが改善されたリポソーム製剤を提供する。
PCT/JP2008/058768 2007-05-14 2008-05-13 リポソームおよびリポソームの製造方法 Ceased WO2008140081A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP08752648.9A EP2153820A4 (en) 2007-05-14 2008-05-13 LIPOSOME AND METHOD FOR PREPARING THE SAME
JP2009514167A JP5532921B2 (ja) 2007-05-14 2008-05-13 リポソーム
EP19153810.7A EP3494964B1 (en) 2007-05-14 2008-05-13 Liposome and method for producing liposome
US12/599,159 US20100215582A1 (en) 2007-05-14 2008-05-13 Liposome and method for producing liposome
US14/598,603 US9980908B2 (en) 2007-05-14 2015-01-16 Liposome and method for producing liposome

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007127819 2007-05-14
JP2007-127819 2007-05-14

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/599,159 A-371-Of-International US20100215582A1 (en) 2007-05-14 2008-05-13 Liposome and method for producing liposome
US14/598,603 Continuation US9980908B2 (en) 2007-05-14 2015-01-16 Liposome and method for producing liposome

Publications (1)

Publication Number Publication Date
WO2008140081A1 true WO2008140081A1 (ja) 2008-11-20

Family

ID=40002271

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/058768 Ceased WO2008140081A1 (ja) 2007-05-14 2008-05-13 リポソームおよびリポソームの製造方法

Country Status (4)

Country Link
US (2) US20100215582A1 (ja)
EP (2) EP3494964B1 (ja)
JP (2) JP5532921B2 (ja)
WO (1) WO2008140081A1 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010222282A (ja) * 2009-03-23 2010-10-07 Konica Minolta Holdings Inc 内水相を固定化することを特徴とするリポソームの製造方法
JP2010248171A (ja) * 2009-03-23 2010-11-04 Konica Minolta Holdings Inc 二段階乳化によるリポソーム製造方法
WO2011062255A1 (ja) * 2009-11-20 2011-05-26 コニカミノルタホールディングス株式会社 混合有機溶媒を油相として用いる二段階乳化によるリポソームの製造方法
JP2011104572A (ja) * 2009-11-20 2011-06-02 Konica Minolta Holdings Inc リポソームの製造方法およびフロー製造装置
JP4900536B2 (ja) * 2009-07-02 2012-03-21 コニカミノルタホールディングス株式会社 特定の分散剤を含有する外水相を利用する二段階乳化法による単胞リポソームの製造方法、ならびに当該単胞リポソームの製造方法を用いる単胞リポソーム分散液またはその乾燥粉末の製造方法
WO2012053484A1 (ja) * 2010-10-19 2012-04-26 コニカミノルタホールディングス株式会社 水溶性脂質を内水相に添加する二段階乳化法による単胞リポソームの製造方法およびその製造方法により得られる単胞リポソーム
JP2012521389A (ja) * 2009-03-25 2012-09-13 ノバルティス アーゲー 薬物及びｓｉＲＮＡを含有する医薬組成物
JP2021176879A (ja) * 2016-01-11 2021-11-11 メリマック ファーマシューティカルズ インコーポレーティッド 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013004585B1 (pt) 2010-09-20 2021-09-08 Merck Sharp & Dohme Corp Lipídeo catiônico, composição de lnp, e, uso de um lipídeo catiônico
ES2898844T3 (es) 2015-09-18 2022-03-09 Univ Muenchen Tech Ligandos para integrina alphavbeta6, síntesis y usos de los mismos
EP3596105B1 (en) 2017-03-17 2023-12-27 Technische Universität München Ligands for integrin .alpha.v.beta.8, synthesis and uses thereof
CN110655585A (zh) * 2018-06-28 2020-01-07 中央研究院 合成多肽及其用途
CN113785975B (zh) * 2021-09-09 2023-08-29 天津医科大学 精胺、亚精胺脂质体在抗氧化、抗衰老中的应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH093093A (ja) 1995-06-21 1997-01-07 Nippon Oil & Fats Co Ltd コレステロール誘導体
JP2001139460A (ja) 1999-11-12 2001-05-22 Asahi Kasei Corp リポソームの調製方法
JP2003119120A (ja) * 2001-10-12 2003-04-23 Masahiko Abe リポソームの製造方法、及び該リポソームを含有する化粧料、及び皮膚外用剤
JP2005162678A (ja) 2003-12-03 2005-06-23 Konica Minolta Medical & Graphic Inc リポソーム用脂質、リポソームおよびそれらの製造方法
JP2005538967A (ja) 2002-06-28 2005-12-22 プロティバ バイオセラピューティクス リミテッド リポソーム製造方法および装置
JP2006028061A (ja) 2004-07-14 2006-02-02 Kyoto Univ 核酸の肝臓へのターゲティング
JP2006272196A (ja) * 2005-03-29 2006-10-12 Toshiba Corp 複合型微粒子の製造方法及び複合型微粒子の製造装置
WO2006115155A1 (ja) * 2005-04-21 2006-11-02 Konica Minolta Medical & Graphic, Inc. リポソーム含有製剤およびその製造方法
WO2007032225A1 (ja) * 2005-09-15 2007-03-22 Kyoto University リポソーム、リポソームの製造方法及び微小反応空間内での反応制御方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252263A (en) * 1986-06-16 1993-10-12 The Liposome Company, Inc. Induction of asymmetry in vesicles
DE3776763D1 (ja) * 1986-06-16 1992-03-26 The Liposome Co.,Inc., Princeton, N.J., Us
US5204112A (en) * 1986-06-16 1993-04-20 The Liposome Company, Inc. Induction of asymmetry in vesicles
JPS63119847A (ja) * 1986-11-07 1988-05-24 Shimadzu Corp リポソ−ムの製造方法
WO1993000156A1 (fr) * 1991-06-29 1993-01-07 Miyazaki-Ken Emulsions monodispersees simples et doubles et procede de production
EP0546174B1 (en) * 1991-06-29 1997-10-29 Miyazaki-Ken Monodisperse single and double emulsions and production thereof
US5552155A (en) * 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
US5554382A (en) * 1993-05-28 1996-09-10 Aphios Corporation Methods and apparatus for making liposomes
CA2184834A1 (en) * 1994-03-11 1995-09-14 Yoshiyuki Mori Liposome preparation
WO1995027478A1 (en) * 1994-04-12 1995-10-19 The Liposome Company, Inc. Fusogenic liposomes and methods of making and using same
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
JP4296341B2 (ja) * 2000-10-13 2009-07-15 独立行政法人産業技術総合研究所 リポソームの製造方法およびその装置
US20070220907A1 (en) 2006-03-21 2007-09-27 Ehlers Gregory A Refrigeration monitor unit
CA2492080A1 (en) * 2002-06-26 2004-01-08 Medigene Oncology Gmbh Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
US20040197392A1 (en) * 2003-01-10 2004-10-07 Knut-Egil Loekling pH-sensitive liposomes
WO2004087097A2 (en) * 2003-03-31 2004-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
WO2004089339A2 (en) * 2003-03-31 2004-10-21 Alza Corporation Lipid particles having asymmetric lipid coating and method of preparing same
JP2005170923A (ja) * 2003-10-21 2005-06-30 Konica Minolta Medical & Graphic Inc リポソーム含有ｘ線造影剤およびその製造方法
WO2005053643A1 (ja) * 2003-12-01 2005-06-16 Mitsubishi Pharma Corporation リポソーム
JP2005225822A (ja) * 2004-02-13 2005-08-25 Konica Minolta Medical & Graphic Inc リポソーム含有ｘ線造影剤
EP1776948B1 (en) * 2004-08-11 2015-12-09 Konica Minolta Medical & Graphic, Inc. Method of producing liposome-containing preparation
JP2006069930A (ja) * 2004-08-31 2006-03-16 Konica Minolta Medical & Graphic Inc リポソームおよびその前駆体エマルション混合物
JP2006069929A (ja) * 2004-08-31 2006-03-16 Konica Minolta Medical & Graphic Inc 真菌症治療製剤およびその製造方法
AU2005303251A1 (en) * 2004-11-10 2006-05-18 Konica Minolta Medical & Graphic, Inc. Pharmaceutical preparation containing covered magnetic particles, manufacturing method thereof and diagnostic therapeutic system
JP2006162678A (ja) * 2004-12-02 2006-06-22 Asahi Glass Co Ltd 光ファイバの光伝送特性の制御方法および光ファイバシステム
JP5085313B2 (ja) * 2005-01-28 2012-11-28 協和発酵キリン株式会社 被覆微粒子の製造方法
JP4815868B2 (ja) * 2005-05-10 2011-11-16 三菱電機株式会社 表示装置
WO2008121721A2 (en) * 2007-03-28 2008-10-09 Portola Pharmaceuticals, Inc. Targeted delivery and expression of procoagulant hemostatic activity
JP5344558B2 (ja) * 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH093093A (ja) 1995-06-21 1997-01-07 Nippon Oil & Fats Co Ltd コレステロール誘導体
JP2001139460A (ja) 1999-11-12 2001-05-22 Asahi Kasei Corp リポソームの調製方法
JP2003119120A (ja) * 2001-10-12 2003-04-23 Masahiko Abe リポソームの製造方法、及び該リポソームを含有する化粧料、及び皮膚外用剤
JP2005538967A (ja) 2002-06-28 2005-12-22 プロティバ バイオセラピューティクス リミテッド リポソーム製造方法および装置
JP2005162678A (ja) 2003-12-03 2005-06-23 Konica Minolta Medical & Graphic Inc リポソーム用脂質、リポソームおよびそれらの製造方法
JP2006028061A (ja) 2004-07-14 2006-02-02 Kyoto Univ 核酸の肝臓へのターゲティング
JP2006272196A (ja) * 2005-03-29 2006-10-12 Toshiba Corp 複合型微粒子の製造方法及び複合型微粒子の製造装置
WO2006115155A1 (ja) * 2005-04-21 2006-11-02 Konica Minolta Medical & Graphic, Inc. リポソーム含有製剤およびその製造方法
WO2007032225A1 (ja) * 2005-09-15 2007-03-22 Kyoto University リポソーム、リポソームの製造方法及び微小反応空間内での反応制御方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 179, 1991, pages 280 - 285
BIOPHYS. J., vol. 35, 1981, pages 637 - 652
CHEM. PHARM. BULL., vol. 53, 2005, pages 871 - 880
PAUTOT S. ET AL.: "Production of Unilamellar Vesicles Using an Inverted Emulsion", LANGMUIR, vol. 19, no. 7, 19 February 2003 (2003-02-19), pages 2870 - 2879, XP008123065 *
See also references of EP2153820A4 *
SUMMARY OF THE ANNUAL MEETING OF THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 127, no. 1, pages 205

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010248171A (ja) * 2009-03-23 2010-11-04 Konica Minolta Holdings Inc 二段階乳化によるリポソーム製造方法
JP2010222282A (ja) * 2009-03-23 2010-10-07 Konica Minolta Holdings Inc 内水相を固定化することを特徴とするリポソームの製造方法
JP2012521389A (ja) * 2009-03-25 2012-09-13 ノバルティス アーゲー 薬物及びｓｉＲＮＡを含有する医薬組成物
JP4900536B2 (ja) * 2009-07-02 2012-03-21 コニカミノルタホールディングス株式会社 特定の分散剤を含有する外水相を利用する二段階乳化法による単胞リポソームの製造方法、ならびに当該単胞リポソームの製造方法を用いる単胞リポソーム分散液またはその乾燥粉末の製造方法
JP2012055885A (ja) * 2009-07-02 2012-03-22 Konica Minolta Holdings Inc 特定分散剤を含有する外水相を利用する二段階乳化法によるリポソームの製造方法、ならびに当該リポソームの製造方法を用いるリポソーム分散液またはその乾燥粉末の製造方法およびそれにより製造されるリポソーム分散液またはその乾燥粉末
JPWO2011062255A1 (ja) * 2009-11-20 2013-04-11 コニカミノルタホールディングス株式会社 混合有機溶媒を油相として用いる二段階乳化によるリポソームの製造方法
WO2011062255A1 (ja) * 2009-11-20 2011-05-26 コニカミノルタホールディングス株式会社 混合有機溶媒を油相として用いる二段階乳化によるリポソームの製造方法
JP2011104572A (ja) * 2009-11-20 2011-06-02 Konica Minolta Holdings Inc リポソームの製造方法およびフロー製造装置
WO2012053484A1 (ja) * 2010-10-19 2012-04-26 コニカミノルタホールディングス株式会社 水溶性脂質を内水相に添加する二段階乳化法による単胞リポソームの製造方法およびその製造方法により得られる単胞リポソーム
JP5838970B2 (ja) * 2010-10-19 2016-01-06 コニカミノルタ株式会社 水溶性脂質を内水相に添加する二段階乳化法による単胞リポソームの製造方法およびその製造方法により得られる単胞リポソーム
JP2021176879A (ja) * 2016-01-11 2021-11-11 メリマック ファーマシューティカルズ インコーポレーティッド 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害
US11787781B2 (en) 2016-01-11 2023-10-17 Celator Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and RAD3-related protein (ATR)
JP2024023349A (ja) * 2016-01-11 2024-02-21 メリマック ファーマシューティカルズ インコーポレーティッド 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害
JP7439023B2 (ja) 2016-01-11 2024-02-27 メリマック ファーマシューティカルズ インコーポレーティッド 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害

Also Published As

Publication number Publication date
EP2153820A1 (en) 2010-02-17
US20100215582A1 (en) 2010-08-26
JP5532921B2 (ja) 2014-06-25
US20150125393A1 (en) 2015-05-07
EP3494964A1 (en) 2019-06-12
JP2014159460A (ja) 2014-09-04
EP3494964B1 (en) 2021-04-07
EP2153820A4 (en) 2013-12-25
JPWO2008140081A1 (ja) 2010-08-05
US9980908B2 (en) 2018-05-29
JP5831588B2 (ja) 2015-12-09

Similar Documents

Publication Publication Date Title
WO2008140081A1 (ja) リポソームおよびリポソームの製造方法
WO2007005754A3 (en) Liposomal delivery vehicle for hydrophobic drugs
WO2012031175A3 (en) Nanoparticle-based tumor-targeted drug delivery
EP4309657A3 (en) Remote loading of sparingly water-soluble drugs into liposomes
EP4233841A3 (en) Small liposomes for delivery of immunogen-encoding rna
WO2007117550A3 (en) Methods for coacervation induced liposomal encapsulation and formulations thereof
WO2010013250A3 (en) Microcapsules comprising active ingredients and a metal oxide shell, a method for their preparation and uses thereof
WO2012122313A3 (en) Targeted nanocarrier systems for delivery of actives across biological membranes
WO2009130225A3 (en) Self-microemulsifying systems incorporated into liquid core microcapsules
WO2009138473A3 (en) Intracellular antibody delivery
GB0617480D0 (en) Novel nanoparticles
WO2011092708A3 (en) Liposomes comprising amphipathic drugs and method for their preparation
WO2012153338A3 (en) Liposomes comprising polymer-conjugated lipids and related uses
WO2010078569A3 (en) Porous nanoparticle supported lipid bilayer nanostructures
WO2011091065A3 (en) Synthetic nanostructures including nucleic acids and/or other entities
WO2008070538A3 (en) Micellar nanoparticles comprising botulinum toxin
WO2013008240A8 (en) Liposomes co-encapsulating a bisphosphonate and an amphipathic agent
WO2014121235A3 (en) Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes
WO2010079468A3 (en) Delivery particle
WO2011116963A3 (en) Lipid nanoparticle capsules
EP2450031A4 (en) METHOD FOR PRODUCING LIPOSOMES BY A TWO-STEP EMULSIFICATION METHOD USING AN EXTERNAL AQUEOUS PHASE CONTAINING A SPECIFIC DISPERSION AGENT, METHOD FOR PRODUCING A LIPOSOME DISPERSION, OR A CORRESPONDING DRY POWDER USING THE LIPOSOME PRODUCTION METHOD AND LIPOSOME DISPERSION OR DRY CORRESPONDING POWDER PRODUCED IN THIS WAY
WO2009102121A3 (ko) 약물 전달용 고형 지질 나노입자, 그 제조방법, 및 그 나노입자를 포함하는 주사제
WO2008087803A1 (ja) 抗酸化成分を封入したイオントフォレーシス用リポソーム製剤
WO2012117385A3 (en) Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it
WO2008096779A1 (ja) Ｃ７０含有リポソームおよびその製造方法、並びにその利用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08752648

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009514167

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12599159

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2008752648

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE